Caroline Caperton, MD, MSPH

12/21/2025

Recent research explores a new vaccine for food allergy management. A novel approach called the IgE-K vaccine is showing significant promise in early preclinical studies, with the potential to offer long-lasting protection from anaphylaxis with infrequent dosing if it proves effective in humans. IgE is the central antibody that drives allergic reactions, and IgE-K works by training the immune system to block IgE before it can bind to the immune cells responsible for triggering severe symptoms. In early research, the vaccine prompted the body to generate durable blocking antibodies that neutralize IgE and prevent the activation of these reaction-initiating cells. The results have been encouraging, with humanized mice demonstrating protection for up to a year following treatment. While further research is needed, this development represents a potentially transformative step forward. Advances like this underscore the momentum in food allergy science, and the growing hope for safer, more effective solutions. Read more here: https://bit.ly/4q9Ggta

12/21/2025

DBV Technologies has announced positive topline results from the Phase 3 VITESSE clinical trial evaluating the investigational VIASKIN® Peanut patch in children ages 4–7 living with peanut allergy.

The study met its primary endpoint, with 46.6% of children using the patch meeting treatment response criteria after 12 months, compared to 14.8% in the placebo group. Children in the treatment group were able to tolerate significantly greater amounts of peanut protein, indicating increased protection against accidental exposure. Safety results were consistent with prior studies, with most side effects reported as mild to moderate skin reactions at the patch site, and treatment-related anaphylaxis reported as rare.

While the VIASKIN® Peanut patch is still investigational and not yet approved by the FDA, progress like this helps bring the food allergy community closer to additional, non-invasive treatment options.

We are deeply grateful to every family and researcher helping shape the future of food allergy care.

12/06/2025

https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/vaccine-myth-fact

The AAAAI offers information on vaccines myths and facts written and reviewed by experts on allergies.

12/05/2025

Over the past decades, doctors and researchers have learned a lot about food allergies, conducting many studies that have helped us get closer to understanding why such allergies might occur and, potentially, preventing them from developing. The current understanding is that exposing young children....

11/30/2025

HHS head Robert F. Kennedy Jr. shared controversial views on food allergies this week:
- U.S. government will fund a study looking for a link between aluminum in vaccines and food allergies. (Much science refutes this idea.)
- He questioned findings on the early introduction of foods like peanut and egg in babies for allergy prevention. (Much science backs early intro.)

The better news: he and federal health agency leaders spoke at the Food Allergy Fund's forum in support of finding food allergy's root causes. Allergic Living speaks to experts Zachary Rubin, MD and Dr. Gideon Lack. See our report: https://www.allergicliving.com/2025/11/20/rfk-jr-plans-vaccine-and-food-allergy-study-science-disagrees/ and go inside what's known on the science of .

Food Allergy Fund Children's Hospital of Philadelphia Food Allergy Science Initiative FASI

11/22/2025

The U.S. Centers for Disease Control and Prevention (CDC) recently added misleading claims to its autism webpage. We want to be clear: decades of high-quality, large-scale studies show that vaccines do not cause autism. "Parents deserve peace of mind. Decades of rigorous research have shown vaccines do not cause autism," said Dr. Susan Kressly, president of the American Academy of Pediatrics. "Vaccines are one of the safest and most effective ways to protect children’s health and help them thrive."

The American Academy of Pediatrics stands with members of the autism community who have asked for support in stopping this rumor from spreading any further. Learn more: https://bit.ly/4rbx4FX

11/20/2025

Thanksgiving is about inclusion 🤎

11/20/2025

FARE is excited to share an important update that’s improving access to life-saving medication. Patients with commercial insurance may now be able to get neffy (epinephrine nasal spray) for as little as $0 through the Co-Pay Savings Program.
Despite the barriers from PBMs and health plans, ARS Pharmaceuticals is helping expand access to a needle-free epinephrine option. This step represents meaningful progress toward making epinephrine more available to those who need it most, bringing innovation closer within reach. Read more here: https://bit.ly/3WimGy7
Book an appointment here: https://bit.ly/3JlQ97l

11/20/2025

Need a biscuit free from wheat, milk, and eggs? We got you.

For the recipe and tips on making the perfect biscuit, check out: https://community.kidswithfoodallergies.org/blog/flaky-biscuits-recipe-dairy-free-egg-free-wheat-gluten-free

11/20/2025

WK Allergy is delighted to welcome Dr. Priyal Upadhyay to our group! She is a board-certified Allergist/Immunologist and Pediatrician specializing in the care of adults and children with allergic needs.

We are accepting new patients & would love to care for you & your family.
Call 318-212-4824 (ITCH).

11/08/2025

10/24/2025

The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps.